SKL20540 / SK Bio - LARVOL DELTA

SK Biopharm widened loss and doubled sales Q3, first report since IPO (Pulse) - "A Phase 1 study of SKL20540, an investigational schizophrenia drug, was completed in Korea in Oct. Phase 3 trials are scheduled to begin in Japan, China and Korea early next year."

New P3 trial • CNS Disorders • Schizophrenia

SK Biopharmaceuticals to expand global presence with IPO (Korea Biomedical Review) - "'We will reinvest public funds secured through the IPO into researching, developing, and commercializing new drugs,' Cho said....New drugs mentioned by Cho include Carisbamate (Lennox-gastaut syndrome treatment), Relenopride (rare neurological disease treatment), SKL13865 (attention deficit hyperactivity disorder treatment), SKL20540 (schizophrenia treatment), SKL-PSY (manic depression treatment), and SKL24741 (epilepsy treatment)."

Financing • CNS Disorders • Depression • Schizophrenia